1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

Cancer Markers

  • March 2016
  • 155 pages
  • Kalorama Information
Report ID: 3756528

Summary

Table of Contents

Search Inside

Cancer is the number two cause of death, behind only cardiovascular disease. The most common types of cancer worldwide include breast cancer, colorectal cancer, lung cancer, and prostate cancer. For these and other types of cancer, novel biomarkers, therapies, and diagnostic tests are being developed. Cancer Markers provides market assessment, estimate and competitive analysis for tests for oncology that use biomarkers. This includes a range of technologies made by scores of companies. The report contains products designed to determine risk for cancer, screen for cancer, test for cancer, aid in prognosis and personalize therapy. Among the technologies are the following:

Histology/Cytology:
Immunohistochemistry
In situ hybridization
Immunoassays - Tumor Markers:
Flow Cytometry
Rapid Tests:
Molecular Marker-Based

Estimates for these segments are provided for 2015 and 2020. In addition, some specific marker breakouts are provided along with significant detail of products on the market. This report reviews the progression of cancer diagnostic technologies over the past 10-15 years and notes some trends in test strategies as well.

Cancer Markers provides the following data:
Worldwide Cancer Biomarkers Diagnostic Market - 2015 and 2020 (IHC, ISH, Immunoassays, Flow, Rapid, Molecular)
Selected International Agreements
Worldwide Cancer Biomarkers Diagnostic Market Percentage (IHC, ISH, Flow Cytometry, Molecular-Based Assays, NMP22, FOB, PSA, CEA, CA125, AFP, Other Tumor Markers)
Estimated Global Incidence and Mortality due to Cancer, 2012 - By Regions of the World
Selected Widely Used Tumor Markers
Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels for Cancer Screening, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels to Predict Prognosis of Cancer, and Companies Developing/Marketing These Biomarkers
Selected Biomarkers and Biomarker Panels to Predict Response to Therapy, and Companies Developing/Marketing These Biomarkers
Selected FDA Cleared/Approved Companion Diagnostic Tests, and Companies Developing/Marketing These Biomarkers
Selected Companies Developing/Marketing Cancer Tests
Common Next Generation Molecular Test Traits
Selected Sample Preparation Reagents
Selected Cancer Test Innovations, 2015

This report contains company profiles, including coverage of the following:
Abbott Laboratories
Alere Inc. (Abbott)
bioMerieux SA
Hologic, Inc.
Illumina, Inc.
QIAGEN N.V.
Roche
Thermo Fisher Scientific, Inc.

The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics and personalized medicine.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending ...

Renal cell cancer (RCC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

  • $ 6995
  • Industry report
  • May 2017
  • by GBI Research

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline Summary Hematological cance ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.